Sonescence, Inc.

Sonescence is developing Ultrasonic Drug Dispersion, a genuine breakthrough in drug delivery. The lead product provides a 5-minute cure for serious wound infections including necrotizing fasciitis and those caused by MRSA. Using an FDA cleared device owned by the company and approved antibiotics, more than 140 patients have already been treated and the lead product IND is now in Phase 2.

Serious skin and soft tissue infections, whether surgical site infections, trauma infections, chronic wounds or diabetic ulcers, afflict well over 1M people in the US annually, cost tens to hundreds of thousands of dollars per patient and frequently result in limb loss or death when the infection cannot be controlled by conventional IV antibiotic therapy, surgery or a variety of existing advanced wound care products.

Barry N. Silberg, MD, discovered that by using a device that he previously invented, he could administer approved antibiotics to skin and soft tissue at levels 277-times higher than achieved with IVs, with systemic levels 29-fold lower than IVs. This level of antibiotic can eradicate infections caused by drug-resistant pathogens, including MRSA, because the levels exceed the minimal inhibitory concentration (MIC) in which pathogens can grow. Most patients were refractory to standard treatments and many were spared limb amputation.

Company’s Keywords:

medical device, wound healing, mrsa infections, skin & soft tissue infections, drug delivery, antibiotics, surgical site infections, diabetic ulcers, ultrasonic drug dispersion, necrotizing fasciitis, pressure ulcers, advanced wound care